Pathogenic Variants in Cancer Predisposition Genes and Prostate Cancer Risk in Men of African Ancestry.
Journal
JCO precision oncology
ISSN: 2473-4284
Titre abrégé: JCO Precis Oncol
Pays: United States
ID NLM: 101705370
Informations de publication
Date de publication:
2020
2020
Historique:
entrez:
25
8
2020
pubmed:
25
8
2020
medline:
25
8
2020
Statut:
ppublish
Résumé
In studies of men of European ancestry, rare pathogenic variants in DNA repair pathway genes have been shown to be associated with risk of aggressive prostate cancer. The contribution of rare coding variation to prostate cancer risk in men of African ancestry has not been established. We sequenced a panel of 19 DNA repair and cancer predisposition genes in 2,453 African American and 1,151 Ugandan prostate cancer cases and controls. Rare variants were classified as pathogenic or putatively functionally disruptive and examined in association with prostate cancer risk and disease aggressiveness in gene and pathway-level association analyses. Pathogenic variants were found in 75 out of 2,098 cases (3.6%) and 31 out of 1,481 controls (2.1%) (OR=1.82, 95% CI=1.19 to 2.79, P=0.0044) with the association being stronger for more aggressive disease phenotypes (OR=3.10, 95% CI=1.54 to 6.23, P=0.0022). The highest risks for aggressive disease were observed with pathogenic variants in the Rare pathogenic variants in DNA repair genes have appreciable effects on risk of aggressive prostate cancer in men of African ancestry. These findings have potential implications for panel testing and risk stratification in this high-risk population.
Identifiants
pubmed: 32832836
doi: 10.1200/po.19.00179
pmc: PMC7442213
mid: NIHMS1616594
doi:
Types de publication
Journal Article
Langues
eng
Pagination
32-43Subventions
Organisme : NCI NIH HHS
ID : R01 CA165862
Pays : United States
Organisme : NCI NIH HHS
ID : U01 CA164973
Pays : United States
Références
Genome Med. 2015 Jul 28;7:76
pubmed: 26315209
N Engl J Med. 2012 Jan 12;366(2):141-9
pubmed: 22236224
Prostate Cancer. 2011;2011:947870
pubmed: 22111004
Nucleic Acids Res. 2016 Jan 4;44(D1):D862-8
pubmed: 26582918
Mutat Res. 2005 Sep 4;577(1-2):275-83
pubmed: 15922366
Nat Commun. 2018 Jun 11;9(1):2256
pubmed: 29892050
Br J Cancer. 2018 Jul;119(1):96-104
pubmed: 29915322
Am J Epidemiol. 2000 Feb 15;151(4):346-57
pubmed: 10695593
Hum Mutat. 2016 Mar;37(3):235-41
pubmed: 26555599
CA Cancer J Clin. 2017 Jan;67(1):7-30
pubmed: 28055103
N Engl J Med. 2016 Aug 4;375(5):443-53
pubmed: 27433846
Br J Cancer. 2014 Mar 18;110(6):1663-72
pubmed: 24556621
Cancer Biol Ther. 2010 Jun 15;9(12):994-9
pubmed: 20364112
Cancer Res. 2004 Feb 15;64(4):1215-9
pubmed: 14973119
J Glob Oncol. 2016 Feb 17;2(4):181-185
pubmed: 28717700
Nature. 2014 Feb 13;506(7487):185-90
pubmed: 24463508
Cancer Epidemiol Biomarkers Prev. 2014 Nov;23(11):2303-10
pubmed: 24812039
Clin Cancer Res. 2010 Apr 1;16(7):2115-21
pubmed: 20215531
BMC Genomics. 2014 Jan 24;15:63
pubmed: 24460756
Genome Biol. 2017 Apr 27;18(1):77
pubmed: 28449691
Asian J Androl. 2012 May;14(3):409-14
pubmed: 22522501
Nat Commun. 2019 Jan 17;10(1):382
pubmed: 30655571
Nucleic Acids Res. 2013 Feb 1;41(3):e46
pubmed: 23221639
Prostate. 2018 Apr;78(5):370-376
pubmed: 29356057
Nat Genet. 2006 Aug;38(8):904-9
pubmed: 16862161
Nat Genet. 2018 Jul;50(7):928-936
pubmed: 29892016
CA Cancer J Clin. 2018 Nov;68(6):394-424
pubmed: 30207593